JP2022547948A5 - - Google Patents
Info
- Publication number
- JP2022547948A5 JP2022547948A5 JP2022515624A JP2022515624A JP2022547948A5 JP 2022547948 A5 JP2022547948 A5 JP 2022547948A5 JP 2022515624 A JP2022515624 A JP 2022515624A JP 2022515624 A JP2022515624 A JP 2022515624A JP 2022547948 A5 JP2022547948 A5 JP 2022547948A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cgrp
- composition according
- igfr
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897686P | 2019-09-09 | 2019-09-09 | |
| US62/897,686 | 2019-09-09 | ||
| US201962946122P | 2019-12-10 | 2019-12-10 | |
| US62/946,122 | 2019-12-10 | ||
| PCT/US2020/070511 WO2021051130A1 (en) | 2019-09-09 | 2020-09-09 | Combination therapy for the treatment of migraines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547948A JP2022547948A (ja) | 2022-11-16 |
| JP2022547948A5 true JP2022547948A5 (enExample) | 2023-09-27 |
Family
ID=74866081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515624A Pending JP2022547948A (ja) | 2019-09-09 | 2020-09-09 | 片頭痛の処置のための併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12324827B2 (enExample) |
| EP (1) | EP4027984A4 (enExample) |
| JP (1) | JP2022547948A (enExample) |
| AU (1) | AU2020346186A1 (enExample) |
| CA (1) | CA3153776A1 (enExample) |
| WO (1) | WO2021051130A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023133562A1 (en) * | 2022-01-07 | 2023-07-13 | Endosome Therapeutics, Inc. | Methods of treating pain |
| WO2025064583A1 (en) * | 2023-09-18 | 2025-03-27 | Ohio State Innovation Foundation | Treating gliomas with calcitonin gene-related peptide antagonist |
| KR102775899B1 (ko) * | 2023-12-19 | 2025-02-28 | 한림대학교 산학협력단 | 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0597033B1 (en) | 1991-08-01 | 1997-04-09 | Genentech, Inc. | Igf-1 to improve the neural condition |
| US5965520A (en) * | 1996-07-25 | 1999-10-12 | Research Corporation Technologies | Therapeutic treatment of rheumatoid arthritis and polymyalgia rheumatica |
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| EP1131344B1 (en) | 1998-11-19 | 2005-08-03 | ELAN CORPORATION, Plc | Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof |
| CN100439397C (zh) | 2001-02-09 | 2008-12-03 | 基因技术股份有限公司 | Igf-1的结晶 |
| WO2002086105A1 (en) | 2001-04-20 | 2002-10-31 | Chiron Corporation | Delivery of polynucleotide agents to the central nervous sysstem |
| US7439063B2 (en) | 2002-06-11 | 2008-10-21 | Burnham Institute For Medical Research | Neuroprotective synergy of erythropoietin and insulin-like growth factors |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| JP4641942B2 (ja) * | 2003-10-03 | 2011-03-02 | フェーイレン・ナムローゼ・フェンノートシャップ | ヒトおよび動物におけるｉｇｆ−１血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中ｉｇｆ−１レベルを増加できる化合物の使用 |
| EP3069731A1 (en) * | 2005-11-14 | 2016-09-21 | Labrys Biologics Inc. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| CA2689549A1 (en) | 2007-06-08 | 2008-12-18 | Massachusetts Institute Of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
| US20110014117A1 (en) | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
| US8197858B2 (en) | 2009-02-06 | 2012-06-12 | Mark John Zamoyski | Bone microenvironment modulated seizure treatments |
| WO2013016223A2 (en) * | 2011-07-22 | 2013-01-31 | The University Of Chicago | Treatments for migraine and related disorders |
| US20190135927A1 (en) * | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
-
2020
- 2020-09-09 US US16/948,219 patent/US12324827B2/en active Active
- 2020-09-09 EP EP20862880.0A patent/EP4027984A4/en not_active Withdrawn
- 2020-09-09 AU AU2020346186A patent/AU2020346186A1/en not_active Abandoned
- 2020-09-09 WO PCT/US2020/070511 patent/WO2021051130A1/en not_active Ceased
- 2020-09-09 JP JP2022515624A patent/JP2022547948A/ja active Pending
- 2020-09-09 CA CA3153776A patent/CA3153776A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547948A5 (enExample) | ||
| US20230277660A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | |
| JP2023548858A5 (enExample) | ||
| JP2025172841A5 (enExample) | ||
| US20220041745A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses | |
| US20230330224A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | |
| US20230295333A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone | |
| WO2020081881A2 (en) | Method of providing subcutaneous administration of anti-cd38 antibodies | |
| US20200308284A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone | |
| FI4267105T3 (fi) | Vasta-ainekoostumuksia ja niiden käyttömenetelmiä | |
| JP2022525164A5 (enExample) | ||
| CA2537748C (en) | Use of telmisartan for the prevention of vascular headache | |
| EP4526353A2 (en) | Formulations for anti-insulin receptor antibody and uses thereof | |
| JP2023510854A5 (enExample) | ||
| JP2023502398A5 (enExample) | ||
| JP2021522241A5 (enExample) | ||
| Silva et al. | Severe case of intrathecal baclofen withdrawal: a case report | |
| JP2024517087A5 (enExample) | ||
| JP2024500912A5 (enExample) | ||
| WO2006130769A3 (en) | Methods for treatment of growth disorders | |
| JP2024501430A5 (enExample) | ||
| RU2848183C1 (ru) | Лечение болезни паркинсона | |
| US20240358726A1 (en) | Specific therapeutic medical marijuana doses for stress and pain | |
| KR20190110063A (ko) | 항-vegfr-2 항체 | |
| US20230235041A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists |